- Home
- BCYC vs CATX Comparison
BCYC vs CATX Comparison
Compare BCYC & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- CATX
- Stock Information
- Founded
- BCYC 2009
- CATX 1983
- Country
- BCYC United Kingdom
- CATX United States
- Employees
- BCYC N/A
- CATX N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- BCYC Health Care
- CATX Health Care
- Exchange
- BCYC Nasdaq
- CATX Nasdaq
- Market Cap
- BCYC 896.2M
- CATX 782.7M
- IPO Year
- BCYC 2019
- CATX N/A
- Fundamental
- Price
- BCYC $11.66
- CATX $2.78
- Analyst Decision
- BCYC Buy
- CATX Strong Buy
- Analyst Count
- BCYC 9
- CATX 9
- Target Price
- BCYC $33.25
- CATX $17.25
- AVG Volume (30 Days)
- BCYC 295.8K
- CATX 724.0K
- Earning Date
- BCYC 03-04-2025
- CATX 03-04-2025
- Dividend Yield
- BCYC N/A
- CATX N/A
- EPS Growth
- BCYC N/A
- CATX N/A
- EPS
- BCYC N/A
- CATX N/A
- Revenue
- BCYC $36,898,000.00
- CATX $1,557,000.00
- Revenue This Year
- BCYC $41.07
- CATX N/A
- Revenue Next Year
- BCYC N/A
- CATX N/A
- P/E Ratio
- BCYC N/A
- CATX N/A
- Revenue Growth
- BCYC 48.60
- CATX N/A
- 52 Week Low
- BCYC $11.14
- CATX $2.70
- 52 Week High
- BCYC $28.67
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- BCYC 34.58
- CATX 32.67
- Support Level
- BCYC $11.14
- CATX $2.91
- Resistance Level
- BCYC $13.11
- CATX $3.21
- Average True Range (ATR)
- BCYC 0.69
- CATX 0.20
- MACD
- BCYC 0.08
- CATX -0.03
- Stochastic Oscillator
- BCYC 22.32
- CATX 1.75
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.